Glycogen synthase kinase-3 alpha mRNA (GSK3A mRNA) (GSK3A mRNA)

Glycogen synthase kinase-3 alpha (GSK-3 alpha) mRNA is the messenger RNA transcript that encodes the GSK-3 alpha protein, a serine/threonine kinase critical for regulating glycogen synthesis, insulin signaling, and the Wnt/beta-catenin pathway (UniProt P49840). While GSK-3 alpha shares structural similarities with its isoform GSK-3 beta, it possesses unique physiological functions, such as its specific requirement for the survival of acute myeloid leukemia (AML) cells and its role in skeletal muscle glucose uptake (PubMed: 24618876). Targeting the mRNA transcript with antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) allows for isoform-specific inhibition, a feat difficult to achieve with small-molecule inhibitors that typically target the conserved ATP-binding pocket of both isoforms (PubMed: 18463253). Therapeutic reduction of GSK-3 alpha mRNA has demonstrated potential in improving insulin sensitivity in type 2 diabetes models and inducing differentiation in AML blasts (PubMed: 18463253, PubMed: 24618876). However, the development of such therapies faces challenges including the need for targeted delivery systems and the potential for compensatory activity from the GSK-3 beta isoform.

Other names

GSK3A transcriptGSK-3 alpha mRNAGlycogen synthase kinase 3 alpha mRNA

Antisense oligonucleotide-mediated mRNA degradation via RNase H or RNA interference (RNAi) leading to reduced translation of the GSK-3 alpha protein (PubMed: 18463253).